• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

JPM 2022: Eli Lilly CEO mulls using Novo's double-branding trick on tirzepatide—one...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 12, 2022 at 11:32: AM
via Is there a good reason to split one drug into multiple brands?

Plenty of drugmakers have already made this decision, including Novo Nordisk with its Wegovy and Ozempic GLP-1 drugs. Now, Eli Lilly CEO Dave Ricks is weighing the idea with its blockbuster-in-waiting, tirzepatide.

article source
 




Top Bottom
Back
Quote